SARS-CoV-2 3CLpro-IN-19

• UNSPSC Description:

  SARS-CoV-2 3CLpro-IN-19 (Compound C5a) is a non-covalent, non-peptide SARS-CoV-2 3CLpro inhibitor (IC50s: 0.7 μM). SARS-CoV-2 3CLpro-IN-19 has broad-spectrum activity against Omicron subvariants (BA.5, BQ.1.1, and XBB.1.5) infection in human cells, with EC50 values between 30-69 nM[1].

• Target Antigen:

  SARS-CoV

• Type:

  Reference compound

• Related Pathways:

  Anti-infection

• Applications:

  COVID-19-anti-virus

• Field of Research:

  Infection

• Assay Protocol:

  https://www.medchemexpress.com/sars-cov-2-3clpro-in-19.html

• Solubility:

  10 mM in DMSO

• Smiles:

  CN(C)C1=CC=C(N(C(CC2=C(C(O)=CC=C3)C3=CN=C2)=O)CC4=CC(Cl)=CS4)C=C1

• Molecular Weight:

  451.97

• References & Citations:

  [1]Pérez-Vargas J, et al. A novel class of broad-spectrum active-site-directed 3C-like protease inhibitors with nanomolar antiviral activity against highly immune-evasive SARS-CoV-2 Omicron subvariants. Emerg Microbes Infect. 2023 Dec;12(2):2246594.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported